

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

CLARIFICATION ANNOUNCEMENT AND PROPOSED ON-MARKET SHARE REPURCHASE

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”) on a voluntary basis. Reference is made to the announcements (the “**Announcements**”) of the Company dated January 29, 2024 in relation to a draft bill (the “**Draft Bill**”) introduced in the U.S. House of Representatives, which proposed to restrict U.S. executive agencies from contracting with certain biotechnology providers, and December 6, 2023 in relation to the Proposed Share Repurchase. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company has noted the recent unusual movements in price and trading volume of its Shares on the Stock Exchange. The Company would like to clarify that the Draft Bill is highly preliminary in nature, remains subject to further review and modification by U.S. legislators and has not been enacted into law. The Company also reaffirms that the Chief Executive Officer and Executive Director of the Company, Dr. Chris Chen, has never been employed by the Academy of Military Medical Sciences nor any military-affiliated institution, nor has he received compensation from any military-affiliated institution, either directly or indirectly. Furthermore, the Company does not have a human genomics business or collect human genomic data in its businesses.

The Company emphasizes that its business operation remains sound and continues to progress according to its annual and medium-term strategic plans. The management team is highly confident in the prospects for the Company and currently does not foresee any material adverse change to the business operation and financial position. As a trusted partner in the global health community, the Company has enabled its clients and partners in accelerating and transforming the discovery, development and manufacturing of biologics and delivering medicines that benefit patients worldwide. The Company will continue to execute Share repurchase as previously announced.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, February 4, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.

* *For identification purpose only*